



Press release

Genopole's D4MedTech project chosen by the *Tiers-Lieux d'Expérimentation* call for projects

Project-leader Genopole and the D4MedTech consortium members are proud to be laureates of the call for projects *Tiers-Lieux d'Expérimentation* for eHealth, a part of the France 2030 national strategy. The D4MedTech project will create an environment for the research and development of digital innovations in diabetology.

Évry-Courcouronnes, 5 December 2024 – During an event held at the Palais des congrès d'Issy for the National Day for Innovation in eHealth organized by the Ministry of Health and Access to Healthcare, Aymeric Perchant, coordinator of the Digital Health Acceleration Strategy, announced the laureates of the third wave of the *Tiers-Lieux d'Expérimentation* call for projects, among which was Genopole's D4MedTech project.

This call for projects is part of a multiyear program conferring €63 million over its five-year period from 2023 to 2027. The call finances organizations and structures able to experiment and develop novel digital solutions for "5P" medicine (preventive, predictive, participative, personalized and pertinent). The call seeks to correct a lack of experimentation structures, an identified limiting factor for the development of an eHealth sector in France. Between 2022 and 2024, 37 such environments for experimentation have been chosen over three successive waves of the call, carried out in the name of the French State by the Banque des Territoires.

Selected in the third wave, the D4Medtech project is aimed at developing digital innovations and solutions to structure the care itinerary for diabetes, a major challenge in public health.

"Being chosen by the Tiers-Lieux d'Expérimentation call for projects attests to Genopole's and its partners' excellence in and commitment to health innovation," declares GIP Genopole President Stéphane Beudet. "I warmly congratulate all of the teams and partners involved in this outstanding success. D4MedTech is the manifestation of a shared ambition: transform the diabetology healthcare itinerary thanks to innovative digital solutions while strengthening our position as a center of excellence for eHealth."

Diabetes is truly a global pandemic. In France alone, it affects more than 4 million people, with a particularly marked prevalence in the Île-de-France Administrative Region, where 600,000 people have the disease. The alarming progression of diabetes, especially in younger populations, presents major challenges to health systems:

- Saturation of care-facility capacity associated with complex care-provision needs;
- A lack of infrastructures adapted to monitoring and prevention in patients with mild diabetes;
- Renouncement of care in precarious populations who often see access to it as antagonistic.

In this setting, eHealth processes offer a clear path to improving healthcare provision, preventing complications and optimizing organization within services. D4MedTech is very much within this dynamic, offering a unique framework for experimentation and validation of innovative, patient-centered, digital solutions in 5P medicine.

D4MedTech: complementary competencies for innovation

Conceived to address these challenges, D4MedTech is built upon a unique partnering of hospital, industrial and institutional actors. **Headed by Genopole, the project's consortium comprises the South Île-de-France Medical Center (CHSF), SATT Paris-Saclay, EIT Health France and the Center for Studies and Research for the Intensification of Diabetes Treatment (CERITD).**

The multidisciplinary consortium provides field-leading competencies:

- **Genopole** provides its research and innovation ecosystem and accompaniment programs (Call for Innovative Ideas, Shaker, Gene.io) to support the emergence and development of high-potential projects. With its network of international corporations and investors, Genopole also ensures the coordination of D4MedTech.

- The **CHSF** provides its active patient files and medical expertise, with the support of its clinical research unit. Building upon its integrated offer of intra/extra-hospital care, the CHSF empowers a direct link between patient needs and digital innovations.
- **EIT Health France** enriches the project with its expertise in the development and evaluation of digital medical devices and its role as a catalyst for national and European projects. Its events initiatives and relationship building with strategic partners and sector experts strengthens the D4MedTech dynamic.
- **SATT Paris-Saclay**, a specialist in technology transfers, identifies emerging research projects and accompanies their maturation. This partner plays a key role in the integration of projects within the D4MedTech structure.
- **CERITD** provides its innovation and eHealth expertise, follow-up information on more than 1,350 patients with diabetes, and advanced databases (electronics and genetics). Through its research activities and strategic partnerships, CERITD guarantees a clinical and technical vision to serve patients.

*"The D4MedTech project stands out by its **inclusive approach**," explains Genopole Digital and Biomedical Innovation Manager Natacha Vitrat. "It seeks to reduce health inequality by providing solutions adapted to vulnerable populations—a **major ambition for the territory**. To do so, the project will consolidate the expertise of the consortium's members **within a unique experimental framework** to enable the development, validation and deployment of digital technologies in real conditions. The project opens a path of excellence and a position in eHealth for Genopole, the project's leader. As a Tiers-Lieux d'Expérimentation laureate, D4MedTech benefits from strategic support to accelerate its development and increase its impact. D4MedTech represents a model for territorial collaboration, and targets national and European deployment."*

Digital sciences in health: a lever to transform healthcare provision

In the setting of diabetes, digital technologies offer new vistas for:

- prevention and early detection, thanks to such technologies as predictive tests or artificial intelligence tools;
- complications management, notably through connected devices like continuous glucose monitors or insulin pumps for patient monitoring and therapeutic education;
- organizational optimization to fluidify the provision of care between hospitals and private-practice medicine.

D4MedTech will ease digital innovation aimed at these primary challenges in diabetes. Its unique framework will enable the conception, testing and validation of innovations in real-world conditions while also responding to major issues in public health and strengthening the attractiveness of the eHealth sector.

About Genopole

Genopole is a French biocluster dedicated to research in genetics and biotechnologies in healthcare and the environment. It unites 66 biotech companies, 17 research laboratories and 24 technological platforms, as well as a range of tertiary-level training programs with the University of Évry-Paris Saclay.

Genopole's objectives are to support biotech companies and the transfer of technologies to the industrial sector, favor the development of life sciences research, and promote advanced training programs for those domains.

Under the presidency of Stéphane Beudet, vice-president of the Île-de-France Administrative Region and mayor of Évry-Courcouronnes, and the direction of Gilles Trystram, Genopole is funded primarily by the French State, the Île-de-France Region, the Grand Paris Sud Urban Area and the AFM-Téléthon.

To learn more: <https://www.genopole.fr>



Press contact:

Virginie Boisgontier, PR consultant – virginie.boisgontier@scribacom.fr – +33 (0)7 86 75 02 97

About the South Ile-de-France Medical Center

The South Île-de-France Medical Center (CHSF) ensures healthcare for 900,000 people living in southern Île-de-France, mainly in the Essonne Department and the southwest of the Seine et Marne Department. It provides both local and tertiary care in close to 40 specialties, three of which (diabetology, neurology and hematology) in the university hospital setting. With 1,113 beds, it proposes a large care provision offer in medicine, surgery, obstetrics and psychiatry. Research & innovation is a strategic axis of the hospital's project. Through its clinical research unit and numerous partnerships, particularly with Genopole, the CHSF participated in 265 studies involving 2,160 patients in 2023. With this dynamic of research & innovation, the CHSF climbed to the fifth place among 15 comparable hospital centers in the SIGAPS (system for the identification, management and analysis of scientific publications) regional ranking.

About CERITD (Center for Studies and Research for the Intensification of Diabetes Treatment)

As a center for innovative research and care for patients with diabetes since 2006, the CERITD is profoundly honored to have been chosen among the laureates of the *Tiers-Lieux d'Expérimentation* call for projects targeting the experimentation and development of digital innovations in diabetology.

Both a collective and personal accolade, being chosen by the call is a recognition of our current efforts and an encouragement for those of the future.

The CERITD and its partners have always had the passion of pushing their limits and creating impactful solutions to significantly improve the daily lives of people with diabetes.

About EIT Health France

[EIT Health](#) is a "Knowledge and Innovation Community" (KIC) on health and aging. It was launched on 1 January 2015 and is financed by [the European Institute of Innovation & Technology](#) (EIT), a European Union body. EIT Health is a Horizon 2020 instrument looking to boost innovation via the triangle of knowledge (Innovation, Education, Business), develop solutions for emerging societal challenges, enable products and services that respond to users' needs (patients, health professionals), and, more largely, play a pioneering role in strengthening European industrial competitiveness, improving quality of life for Europeans and safeguarding health systems under the weight of the ever-increasing cost of age-related chronic diseases. EIT Health comprises seven clusters covering all of Europe and bringing together more than 130 partners, including industrials, academics and hubs in the MedTech, BioTech or DigiTech sectors. EIT Health France, which unites more than 40 partners, is based in Paris and headed by Deputy Director Jérôme Fabiano.

For more information, visit [France - EIT Health](#)

Follow us on LinkedIn: [EIT Health France](#); and on X: [@EIThealth_FR](#)

About SATT Paris-Saclay

With the support of its shareholders (Paris-Saclay University, CNRS, Institut Polytechnique de Paris, Bpifrance), SATT Paris-Saclay develops business competitiveness through innovation, valorizing the technologies, competencies and expertise of 16,000 researchers in 300 laboratories within the Paris-Saclay cluster. Its core activity is the maturation of innovation in technological, regulatory and economic terms. SATT Paris-Saclay works in close partnership with businesses to carry out codeveloped maturation projects and advance innovative services. It proposes licensing agreements for mature technologies to industry. SATT Paris-Saclay is a member of the SATT Network.

For more information, visit www.satt-paris-saclay.fr | @SATTsaclay

Since 2014: +€53 million invested for valorization | +165 innovative projects financed | 40 start-ups created